Philip D. Greenberg, M.D.

Venture Partner at Catalio Capital Management

View Live Interactive Profile →

Biography

Catalio Capital Management lists Philip D. Greenberg as a Venture Partner. The firm's profile page gives the current affiliation as Professor of Oncology and Immunology, University of Washington; Investigator, Parker Institute for Cancer Immunotherapy, Fred Hutchinson Cancer Research Center. His stated honours include the Cancer Research Institute William B. Coley Award (2011), the SITC Richard Smalley Memorial Award (2018), fellowship of the AACR Academy (2019) and the American Society of Hematology E. Donnall Thomas Prize (2019). Catalio's page lists him as a co-founder of Targeted Genetics, Juno Therapeutics and Affini-T Therapeutics. A page summariser returned board positions for him identical to those of another venture partner on an adjacent page; that output was discarded as unreliable and no board seats are recorded.

Education

• BA, Washington University, St. Louis
• MD, State University of New York
• Residency, University of California, San Diego
• Postdoctoral Fellow, University of California, San Diego

Sources & References